4.04

0.25% 0.010

After Hours: 4.04

X 4 Pharmaceuticals Inc (XFOR)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

X 4 Pharmaceuticals Inc stock is traded at $4.04, with a volume of 1.22M. It is up +0.25% in the last 24 hours and up +9.49% over the past month. X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Previous Close:

$4.03

Open:

$4.05

24h Volume:

1.22M

Relative Volume:

1.64

Market Cap:

$400.55M

Revenue:

$9.01M

Net Income/Loss:

$-99.72M

P/E Ratio:

-0.8902

EPS:

-4.5381

Net Cash Flow:

$-92.85M

1W Performance:

-4.27%

1M Performance:

+9.49%

6M Performance:

+27.85%

1Y Performance:

+27.04%

1-Day Range:

$4.005

$4.175

1-Week Range:

$3.99

$4.35

52-Week Range:

$2.80

$4.83

X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile

Name

X 4 Pharmaceuticals Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

857-529-8300

Address

61 NORTH BEACON STREET, BOSTON, MA

Employee

Twitter

@x4pharma

Next Earnings Date

2026-08-14

Latest SEC Filings

XFOR's Discussions on Twitter

Compare XFOR vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XFOR X 4 Pharmaceuticals Inc	4.04	399.56M	9.01M	-99.72M	-92.85M	-4.5381
VRTX Vertex Pharmaceuticals Inc	548.05	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	834.04	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,039.78	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.13	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	209.46	45.38B	742.00K	-1.37B	-1.07B	-7.0731

X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-09-26	Initiated	Guggenheim	Buy
Dec-05-25	Resumed	Stifel	Buy
Dec-12-23	Downgrade	B. Riley Securities	Buy → Neutral
Aug-30-23	Resumed	B. Riley Securities	Buy
Dec-22-22	Initiated	Cantor Fitzgerald	Overweight
Dec-12-22	Initiated	Piper Sandler	Overweight
Dec-23-19	Initiated	Oppenheimer	Outperform
Dec-18-19	Initiated	ROTH Capital	Buy
Dec-09-19	Upgrade	Citigroup	Neutral → Buy
Dec-05-19	Initiated	B. Riley FBR	Buy
Jun-07-19	Initiated	Stifel	Buy
Jun-05-19	Initiated	Cowen	Outperform

View All

X 4 Pharmaceuticals Inc Stock (XFOR) Latest News

Aug 20, 2026

Deep Track Capital, LP Boosts X4 Pharmaceuticals (XFOR) Stake by 26.84% - GuruFocus

Aug 20, 2026

Aug 19, 2026

Is OPK Worth Buying as Valuation Meets Improving Business Trends? - TradingView

Aug 19, 2026

X4 (XFOR) Financial Update: Profit Per Share Clears Its Benchmark in Latest Trading; Closing Reaction - vinanet.vn

Aug 19, 2026

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Aug 19, 2026

X4 Pharmaceuticals: Making Progress, But The Market Is Ahead Of The Trial (Rating Downgrade) - Seeking Alpha

Aug 19, 2026

Layoff Tracker: Kolon TissueGene cuts 37 US staffers after Phase 3 fail - BioSpace

Aug 19, 2026

Aug 18, 2026

X4 (XFOR) Share-Price Review: Closes 2.09% Lower at $4.21 in the Current Update; Price-Level Context: the Near-Term Reference Band Stretches From $4.00 to $4.42 in Latest TradingChandelier Stop - vinanet.vn

Aug 18, 2026

Fierce Biotech Layoff Tracker 2026: Kolon cuts workforce after ph. 3 fail; Sanofi sheds 229 staffers - Fierce Biotech

Aug 18, 2026

Aug 17, 2026

C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Study Explores Industry Growth Toward $2.75 Billion - openPR.com

Aug 17, 2026

Aug 14, 2026

Perceptive Advisors (XFOR) reports 8.1% beneficial stake in X4 Pharmaceuticals - Stock Titan

Aug 14, 2026

Supernus Pharmaceuticals (SUPN) CMO Rubin exercises PSUs and withholds shares for tax - Stock Titan

Aug 14, 2026

Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk? - TradingView

Aug 14, 2026

4 Best Pharmaceutical Stocks for 2026 and How to Invest - The Motley Fool

Aug 14, 2026

Deep Track Capital (XFOR) discloses 8.33% X4 Pharmaceuticals stake with capped warrants - Stock Titan

Aug 14, 2026

Aug 13, 2026

X4 Pharmaceuticals President John Volpone Sells 24,576 Shares to Settle Tax on RSU Award - Kalkine Media

Aug 13, 2026

John Volpone Sells 24,576 Shares of X4 Pharmaceuticals (NASDAQ:XFOR) Stock - MarketBeat

Aug 13, 2026

X4 Pharmaceuticals (NASDAQ:XFOR) Chairman Sells $210,615.84 in Stock - MarketBeat

Aug 13, 2026

X4 Pharma chairman Craig R. sells $210,829 in shares - Investing.com

Aug 13, 2026

X4 Pharma chairman Craig R. sells $210,829 in shares By Investing.com - Investing.com India

Aug 13, 2026

X4 Pharmaceuticals Executive Chairman Adam R. Craig Sells 47,436 Shares to Cover RSU Tax Liability - Kalkine Media

Aug 13, 2026

X4 Pharmaceuticals, Inc SEC Filing (Aug 13, 2026) - Stock Titan

Aug 13, 2026

Aug 12, 2026

Industry Analysts Just Made A Dazzling Upgrade To Their X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Revenue Forecasts - simplywall.st

Aug 12, 2026

Aug 11, 2026

Earnings Update: X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Just Reported And Analysts Are Boosting Their Estimates - webull.com

Aug 11, 2026